---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041368"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:23:35.940081+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q2 net loss $13.3M; orphan drug designation for TYRA-300 in achondroplasia

## Summary
- Net loss $13.3M vs $15.1M Q2 2022; cash & equivalents $232.4M as of June 30.
- FDA granted Orphan Drug Designation for TYRA-300 for achondroplasia in July 2023.
- SURF301 Phase 1/2 oncology study enrollment ongoing in Part A and Part B at U.S., EU, Australia sites.
- TYRA-200 Phase 1 study in intrahepatic cholangiocarcinoma on track to dose first patient 2H 2023.
- Strengthened leadership: appointed Dr. Michael Bober as VP Clinical Development and Medical Affairs.

## SEC filing metadata
- accession: 0000950170-23-041368
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017023041368/0000950170-23-041368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017023041368/tyra-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041368
- JSON: https://secwatch.observer/filing/0000950170-23-041368.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041368.txt

## Key facts
- Earnings Releases
  Tyra Biosciences, Inc. reported the quarter ended June 30, 2023 results: net income Second quarter 2023 net loss was $13.3 million.
  - Period: the quarter ended June 30, 2023
  - Net income: Second quarter 2023 net loss was $13.3 million
  - Result: reported results
  source text: Second quarter 2023 net loss was $13.3 million compared to $15.1 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017023041368/0000950170-23-041368-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.